Psyence Group

📍 Toronto, Canada🗓 Founded 2019👥 16 employees💰 Last funded Oct 2020
Biotechnology Research🌐 psyence.com
Website LinkedIn
Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care. We are focused on the scientific research and development of psilocybin medical products for research institutions, clinics and regulatory-compliant psilocybin containing products. We are also developing functional mushroom nutraceutical products for depression, acute anxiety and sleep disorders. Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa. For more information: www.psyence.com
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Psyence Group?
Psyence Group has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Psyence Group last raise funding?
The most recent investment in Psyence Group recorded on gritt.io was in October 2020.
When was Psyence Group founded?
Psyence Group was founded in 2019.
What industry is Psyence Group in?
Psyence Group operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Psyence Group based?
Psyence Group is headquartered in Toronto, Canada.